Mindwalk Holdings Corp (HYFT)

$1.28 +0.10 (8.47%)
Market Cap 54.47M
Revenue (ttm) 17.59M
Net Income (ttm) -21.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -123.31%
Debt to Equity Ratio 0.00
Volume 336,700
Avg Vol 377,972
Day's Range N/A - N/A
Shares Out 46.16M
Stochastic %K 91%
Beta 0.63
Analysts Sell
Price Target $4.00

Company Profile

MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed it...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 620 4187
Address:
Industrious 823 Congress Ave, Suite 300, Austin, United States
Cultler
Cultler Apr. 16 at 1:36 AM
$HYFT
0 · Reply
MOMOdough
MOMOdough Apr. 15 at 10:09 PM
$HYFT it’s alive! About time. Very underrated company based on the ballooned valuations for companies that have 3 employees and no revenue. This company has annual rev which is ramping of 20+mil and 50 employees. Why do people buy junk when they can buy a real company. Only a matter of time until people wake up and this is $10
1 · Reply
kozyman87
kozyman87 Apr. 15 at 10:01 PM
$HYFT Great job on their DD today. I was impressed with the 41 pages of detailed information. Very conservative as the research doesn't give any value to the pipeline, but definitely gives us optionality .....so lots of upside if we start hitting in pipeline terms
0 · Reply
iambaron
iambaron Apr. 15 at 9:24 PM
$HYFT a real AI company… not a shoe company like $BIRD squeezing some fools
0 · Reply
MakeM0ney_444
MakeM0ney_444 Apr. 15 at 9:22 PM
$HYFT buyout soon? Someone knows something…
1 · Reply
Twills08
Twills08 Apr. 15 at 9:07 PM
$HYFT Analyst coverage initiated. Buy rating with a $5 target price…. insider buys in March. This may get interesting. Sympathy $BIRD play?
0 · Reply
TheDuck23
TheDuck23 Apr. 15 at 9:03 PM
$HYFT
0 · Reply
Twills08
Twills08 Apr. 15 at 8:55 PM
$HYFT moving….
0 · Reply
NyseDayTrader
NyseDayTrader Apr. 15 at 8:34 PM
$HYFT I was busy all day when I finally looked at 4 o’clock. The first thought in my head was Jennifer Bath was finally shown the door. one can only dream..
0 · Reply
dudududucharles
dudududucharles Apr. 15 at 5:41 PM
$HYFT LensAI screened 2,000+ influenza sequences and found a single conserved functional feature in every single one. That's the kind of target that could anchor a broadly protective flu vaccine
0 · Reply
Latest News on HYFT
MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

Mar 12, 2026, 8:31 AM EDT - 5 weeks ago

MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

Mar 6, 2026, 4:01 PM EST - 5 weeks ago

MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026

Mar 2, 2026, 8:31 AM EST - 6 weeks ago

MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026

MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics

Jan 27, 2026, 12:01 AM EST - 2 months ago

MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

Jan 14, 2026, 8:00 AM EST - 3 months ago

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

Jan 12, 2026, 7:00 AM EST - 3 months ago

REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

Jan 9, 2026, 8:01 PM EST - 3 months ago

MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline

Dec 15, 2025, 8:30 AM EST - 4 months ago

MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025

Dec 8, 2025, 8:30 AM EST - 4 months ago

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025

MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

Nov 13, 2025, 9:00 AM EST - 5 months ago

MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

Oct 21, 2025, 8:28 AM EDT - 6 months ago

MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

Oct 15, 2025, 7:00 AM EDT - 6 months ago

MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

MindWalk Announces Share Repurchase Program

Oct 9, 2025, 7:00 AM EDT - 6 months ago

MindWalk Announces Share Repurchase Program

MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity

Sep 22, 2025, 7:02 AM EDT - 7 months ago

MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity

MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet

Sep 15, 2025, 8:44 AM EDT - 7 months ago

MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet

ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”

Sep 3, 2025, 8:48 AM EDT - 8 months ago

ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York

Sep 2, 2025, 8:01 AM EDT - 8 months ago

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

Aug 27, 2025, 8:22 AM EDT - 8 months ago

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

Aug 6, 2025, 8:00 AM EDT - 9 months ago

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

Aug 6, 2025, 8:00 AM EDT - 9 months ago

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

Jul 29, 2025, 8:28 AM EDT - 9 months ago

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

Jul 24, 2025, 8:22 AM EDT - 9 months ago

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

Jul 21, 2025, 8:28 AM EDT - 9 months ago

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

Jul 16, 2025, 8:05 AM EDT - 9 months ago

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 14, 2025, 8:01 AM EDT - 9 months ago

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

Jul 7, 2025, 9:00 AM EDT - 10 months ago

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

Jul 3, 2025, 8:19 AM EDT - 10 months ago

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

Jun 24, 2025, 7:02 AM EDT - 10 months ago

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

Jun 12, 2025, 8:01 AM EDT - 11 months ago

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

Jun 5, 2025, 8:01 AM EDT - 11 months ago

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

AMD

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

May 21, 2025, 8:49 AM EDT - 11 months ago

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

May 20, 2025, 8:28 AM EDT - 11 months ago

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

May 12, 2025, 8:01 AM EDT - 1 year ago

IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

AMD

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

Apr 11, 2025, 8:40 AM EDT - 1 year ago

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

Mar 28, 2025, 8:01 AM EDT - 1 year ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

Mar 13, 2025, 7:02 AM EDT - 1 year ago

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

Mar 11, 2025, 10:17 PM EDT - 1 year ago

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

Mar 5, 2025, 8:01 AM EST - 1 year ago

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

Feb 26, 2025, 8:01 AM EST - 1 year ago

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

ImmunoPrecise Antibodies Announces Key Leadership Changes

Feb 24, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies Announces Key Leadership Changes

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

Feb 20, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture

Jan 27, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

Jan 22, 2025, 7:02 AM EST - 1 year ago

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

Jan 17, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

IPA Announces Resignation of Chief Financial Officer

Dec 31, 2024, 7:56 PM EST - 1 year ago

IPA Announces Resignation of Chief Financial Officer

$116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors

Dec 30, 2024, 10:03 PM EST - 1 year ago

$116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors

MMI

ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases

Dec 23, 2024, 8:30 AM EST - 1 year ago

ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases

IPA to Present at The Microcap Conference 2025

Dec 19, 2024, 10:15 AM EST - 1 year ago

IPA to Present at The Microcap Conference 2025

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025

Dec 10, 2024, 8:30 AM EST - 1 year ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025

IPA to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Dec 4, 2024, 8:00 AM EST - 1 year ago

IPA to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Cultler
Cultler Apr. 16 at 1:36 AM
$HYFT
0 · Reply
MOMOdough
MOMOdough Apr. 15 at 10:09 PM
$HYFT it’s alive! About time. Very underrated company based on the ballooned valuations for companies that have 3 employees and no revenue. This company has annual rev which is ramping of 20+mil and 50 employees. Why do people buy junk when they can buy a real company. Only a matter of time until people wake up and this is $10
1 · Reply
kozyman87
kozyman87 Apr. 15 at 10:01 PM
$HYFT Great job on their DD today. I was impressed with the 41 pages of detailed information. Very conservative as the research doesn't give any value to the pipeline, but definitely gives us optionality .....so lots of upside if we start hitting in pipeline terms
0 · Reply
iambaron
iambaron Apr. 15 at 9:24 PM
$HYFT a real AI company… not a shoe company like $BIRD squeezing some fools
0 · Reply
MakeM0ney_444
MakeM0ney_444 Apr. 15 at 9:22 PM
$HYFT buyout soon? Someone knows something…
1 · Reply
Twills08
Twills08 Apr. 15 at 9:07 PM
$HYFT Analyst coverage initiated. Buy rating with a $5 target price…. insider buys in March. This may get interesting. Sympathy $BIRD play?
0 · Reply
TheDuck23
TheDuck23 Apr. 15 at 9:03 PM
$HYFT
0 · Reply
Twills08
Twills08 Apr. 15 at 8:55 PM
$HYFT moving….
0 · Reply
NyseDayTrader
NyseDayTrader Apr. 15 at 8:34 PM
$HYFT I was busy all day when I finally looked at 4 o’clock. The first thought in my head was Jennifer Bath was finally shown the door. one can only dream..
0 · Reply
dudududucharles
dudududucharles Apr. 15 at 5:41 PM
$HYFT LensAI screened 2,000+ influenza sequences and found a single conserved functional feature in every single one. That's the kind of target that could anchor a broadly protective flu vaccine
0 · Reply
MVPnash
MVPnash Apr. 15 at 1:36 PM
$HYFT
0 · Reply
MexicoCity
MexicoCity Apr. 15 at 1:36 AM
$HYFT
0 · Reply
MakeM0ney_444
MakeM0ney_444 Apr. 14 at 3:26 PM
$HYFT will it hold? Any news?
1 · Reply
JeffingAround
JeffingAround Apr. 14 at 1:36 PM
$HYFT
0 · Reply
TheDuck23
TheDuck23 Apr. 14 at 6:55 AM
$HYFT waiting on news
0 · Reply
RuneLite
RuneLite Apr. 14 at 1:36 AM
$HYFT
0 · Reply
MakeM0ney_444
MakeM0ney_444 Apr. 13 at 8:08 PM
$HYFT one fucking penny. This is just dead money dammit I feel like an idiot
0 · Reply
wowstepbro
wowstepbro Apr. 13 at 6:32 PM
$HYFT the LensAI contract shifts this from project based to contracted recurring revenue. That's the pivot that changes how you model the business
1 · Reply
Freeballing
Freeballing Apr. 13 at 1:36 PM
$HYFT
0 · Reply
chucky1110
chucky1110 Apr. 13 at 1:14 PM
$HYFT Is there any light at the end of this tunnel? Bubbles, say something!
1 · Reply
LebronBOOM
LebronBOOM Apr. 13 at 1:35 AM
$HYFT
0 · Reply
Scam_Likely
Scam_Likely Apr. 13 at 12:35 AM
$HYFT Between the Trump Dump and Blood BATH... we don't stand a chance... she can blame the greater market and take no responsibility... but anyone who believed in her and/or the company.. we get fuqued.
2 · Reply